Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer


Bladder | Distal Urethral Cancer | Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Proximal Urethral Cancer | Recurrent Bladder Cancer | Recurrent Prostate Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Urethral Cancer | Stage IV Bladder Cancer | Stage IV Prostate Cancer | Transitional Cell Carcinoma of the Bladder | Urethral Cancer Associated With Invasive Bladder Cancer

What is the purpose of this trial?

This randomized phase III trial is studying gemcitabine hydrochloride, cisplatin, and bevacizumab to see how well they work compared with gemcitabine hydrochloride, cisplatin, and placebo in treating patients with advanced urinary tract cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether gemcitabine hydrochloride and cisplatin are more effective when given together with or without bevacizumab in treating patients with urinary tract cancer.

Participation Guidelines

18 Years and older

Click here for detailed information about who can participate in this trial.

National Cancer Institute (NCI)
Last Updated:
Study HIC#: